Immunocore Advances Half-Life Extended Cancer Treatment With First Patient Dosed

BenzingaDec 23 07:03 ET

Express News | Immunocore Announces First Patient Dosed in the Phase 1 Trial of Imc-P115C, a Half-Life Extended (Hle) Immtac Candidate in Patients With Tumors That Express Prame

ReutersDec 23 07:00 ET

Jefferies Maintains Immunocore(IMCR.US) With Buy Rating, Cuts Target Price to $45

Moomoo NewsDec 20 13:31 ET · Ratings

Express News | Immunocore Begins Phase 1/2 Trial of IMC-R117C, The First Immunotherapy Targeting PIWIL1 In Advanced Gastrointestinal Cancers

BenzingaDec 17 07:05 ET

Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry?

Simply Wall StDec 14 08:41 ET

Morgan Stanley Upgrades PTC, Cuts Immuneering, Amicus

Seeking AlphaDec 13 14:42 ET